logo
Share SHARE
FONT-SIZE Plus   Neg

EXACT Sciences Says It Submitted Final Module Of PMA For Cologuard To The FDA

EXACT Sciences Corp. (EXAS), a molecular diagnostics company focused on the early detection and prevention of colorectal cancer, Monday said that it submitted the final module of the premarket approval or PMA for Cologuard, the company's stool DNA or sDNA colorectal cancer screening test, to the U.S. Food and Drug Administration or FDA. The final module which was submitted on June 7, comprised of data from the company's DeeP-C clinical trial. The trial analyzed data from about 10,000 patients at 90 sites between the ages of 50 and 84 who were at average risk for colorectal cancer.

EXACT Sciences also announced that the role of COO Maneesh Arora would now also include the oversight of U.S. sales and marketing. The company is also in the search for a senior financial officer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Diplomatic ties have been restored, so Cuba will surely see an influx of massive cruise ships and curious Americans. Following the rebound seen in the previous session, stocks continued to recover from Monday's sell-off during trading on Wednesday. The markets benefited from a positive reaction to the latest news about Greece as well as some upbeat U.S. economic data. Continuing efforts to normalize relations, President Barack Obama announced Wednesday the U.S. and Cuba will re-open embassies in each country's respective capitals later this month. Obama described the move as a demonstration that the U.S. and Cuba don't have to be imprisoned by the past.
comments powered by Disqus
RELATED NEWS
Trade EXAS now with 
Follow RTT